Rapport Therapeutics, Inc. (RAPP)
NASDAQ: RAPP · Real-Time Price · USD
9.78
-0.27 (-2.69%)
Mar 31, 2025, 12:51 PM EDT - Market open

Rapport Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022
Period Ending
Dec '24 Dec '23 Dec '22
Net Income
-78.31-34.79-11.62
Depreciation & Amortization
0.840.110.02
Asset Writedown & Restructuring Costs
--5.45
Loss (Gain) From Sale of Investments
-3.21-0.08-
Stock-Based Compensation
10.243.530.61
Other Operating Activities
8.031.390.38
Change in Accounts Payable
-0.350.861.58
Change in Other Net Operating Assets
-2.071.80.05
Operating Cash Flow
-64.83-27.18-3.54
Capital Expenditures
-2.41-1.64-0.31
Sale (Purchase) of Intangibles
---5.45
Investment in Securities
-167.74-77.22-
Investing Cash Flow
-170.14-78.86-5.76
Total Debt Issued
--8.73
Net Debt Issued (Repaid)
--8.73
Issuance of Common Stock
157.710.050.03
Repurchase of Common Stock
--0-
Other Financing Activities
--0.13-0.11
Financing Cash Flow
221.63145.1443.29
Net Cash Flow
-13.3439.133.99
Free Cash Flow
-67.23-28.82-3.85
Free Cash Flow Per Share
-3.24-19.14-4.95
Levered Free Cash Flow
-44.47-17.43-
Unlevered Free Cash Flow
-44.47-17.43-
Change in Net Working Capital
1.23-3.19-
Updated Mar 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q